HSD31 Treatment Patterns of Relapsing-Remitting Multiple Sclerosis within the High Cost Drug Law (RICARTE SOTO LAW) Program in Chile from July 2017 to November 2021
The Ricarte Soto Law (RSL) is a Public Health program that provides universal coverage for high-cost treatment diseases. For Relapsing-Remitting Multiple Sclerosis (RRMS), this is a “rescue” program which covers financial costs of Disease Modifying Treatments (DMT) after first-line immunomodulatorshas failed . It started in July’17 covering Natalizumab and Fingolimod. By July’19 Ocrelizumab, Alemtuzumab and Cladribine were included. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: F Cofre, MF Rozas, L Galleguillos, A Rada Source Type: research
EE321 A Re-Examination of a Cost-Minimization Analysis in Multiple Sclerosis: Assessing Biases from the Inaccurate Assumption of Equal Effectiveness Using Probabilistic Sensitivity Analysis (PSA)
This study uses PSA to estimate cost-effectiveness and associated decision uncertainty for the CMA and CEA. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: C Pretorius, B Rittenhouse, T Eguale, JD Kallich Source Type: research
EE288 A Cost-Effectiveness Analysis of Biologic Compared with Chemical Disease Modifying Drugs in Treating Multiple Sclerosis in US
Multiple sclerosis (MS) is a chronic immune mediated neurodegenerative disease of the central nervous system with US prevalence of ∼900,000 and high economic burden. Medical care for MS involves high-cost diseases modifying therapies (DMT). The current study aims to compare the cost-effectiveness of best-selling biologics (Ocrelizumab, Natalizumab, Alemtuzumab) with best-selling chemical drugs (Dimethyl Fumarate, Fingolimod) as DMT for MS to support better clinical decision-making. (Source: Value in Health)
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: S Jin, L Amezcua, N Moghavem, W Padula Source Type: research
Comparative safety of high-efficacy disease-modifying therapies in relapsing –remitting multiple sclerosis: a systematic review and network meta-analysis
ConclusionThe commonly reported AEs are generally similar among high-efficacy DMTs. However, based onP scores for most analyzed endpoints, natalizumab and ocrelizumab were shown to be the safest DMTs. Considering the limitations of indirect comparisons, further research is needed to confirm our findings, preferably head-to-head RCTs and large observational studies. (Source: Neurological Sciences)
Source: Neurological Sciences - June 17, 2022 Category: Neurology Source Type: research
Blocking Immune Cell infiltration of the Central Nervous System to Tame Neuroinflammation in Amyotrophic Lateral Sclerosis
Brain Behav Immun. 2022 Jun 7:S0889-1591(22)00156-8. doi: 10.1016/j.bbi.2022.06.004. Online ahead of print.ABSTRACTNeuroinflammation is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, peripheral immune cells were discovered as pivotal players that promptly participate in this process, speeding up neurodegeneration during progression of the disease. In particular, infiltrating T cells and natural killer cells release inflammatory cytokines that switch glial cells toward a pro-inflammatory/detrimental phenotype, and directly attack motor neurons with specific ligand-receptor signals. Here, we asse...
Source: Brain, Behavior, and Immunity - June 10, 2022 Category: Neurology Authors: Stefano Garofalo Germana Cocozza Giovanni Bernardini Julie Savage Marcello Raspa Eleonora Aronica Marie-Eve Tremblay Richard M Ransohoff Angela Santoni Cristina Limatola Source Type: research
Blocking Immune Cell infiltration of the Central Nervous System to Tame Neuroinflammation in Amyotrophic Lateral Sclerosis
Brain Behav Immun. 2022 Jun 7:S0889-1591(22)00156-8. doi: 10.1016/j.bbi.2022.06.004. Online ahead of print.ABSTRACTNeuroinflammation is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, peripheral immune cells were discovered as pivotal players that promptly participate in this process, speeding up neurodegeneration during progression of the disease. In particular, infiltrating T cells and natural killer cells release inflammatory cytokines that switch glial cells toward a pro-inflammatory/detrimental phenotype, and directly attack motor neurons with specific ligand-receptor signals. Here, we asse...
Source: Brain, Behavior, and Immunity - June 10, 2022 Category: Neurology Authors: Stefano Garofalo Germana Cocozza Giovanni Bernardini Julie Savage Marcello Raspa Eleonora Aronica Marie-Eve Tremblay Richard M Ransohoff Angela Santoni Cristina Limatola Source Type: research
Blocking Immune Cell infiltration of the Central Nervous System to Tame Neuroinflammation in Amyotrophic Lateral Sclerosis
Brain Behav Immun. 2022 Jun 7:S0889-1591(22)00156-8. doi: 10.1016/j.bbi.2022.06.004. Online ahead of print.ABSTRACTNeuroinflammation is one of the main hallmarks of amyotrophic lateral sclerosis (ALS). Recently, peripheral immune cells were discovered as pivotal players that promptly participate in this process, speeding up neurodegeneration during progression of the disease. In particular, infiltrating T cells and natural killer cells release inflammatory cytokines that switch glial cells toward a pro-inflammatory/detrimental phenotype, and directly attack motor neurons with specific ligand-receptor signals. Here, we asse...
Source: Brain, Behavior, and Immunity - June 10, 2022 Category: Neurology Authors: Stefano Garofalo Germana Cocozza Giovanni Bernardini Julie Savage Marcello Raspa Eleonora Aronica Marie-Eve Tremblay Richard M Ransohoff Angela Santoni Cristina Limatola Source Type: research
